J Wolf

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. pmc Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
    D Re
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany
    Br J Cancer 86:1333-5. 2002
  2. ncbi request reprint Genetic instability in Hodgkin's lymphoma
    D Re
    Department of Internal Medicine I, University Hospital Cologne, Germany
    Ann Oncol 13:19-22. 2002
  3. ncbi request reprint BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group
    V Diehl
    Department of Internal Medicine, University of Cologne, Germany
    J Clin Oncol 16:3810-21. 1998
  4. ncbi request reprint Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
    M R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    Blood 98:2930-4. 2001
  5. ncbi request reprint BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group
    V Diehl
    Department of Internal Medicine, University of Cologne, Germany
    Ann Oncol 9:S67-71. 1998
  6. ncbi request reprint Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells
    D Re
    Department of Internal Medicine I, University of Cologne, Germany
    Cancer Res 61:2080-4. 2001
  7. ncbi request reprint Lack of BCL10 mutations in Hodgkin's disease-derived cell lines
    D Re
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Strasse 9, 50924 Cologne, Germany
    Br J Haematol 109:420-2. 2000
  8. ncbi request reprint Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells
    M MUSCHEN
    Institute for Genetics, Department of Immunology, University of Cologne, Koln, Germany
    Cancer Res 60:5640-3. 2000
  9. ncbi request reprint Evaluation of the accuracy of FDG-/FLT-PET for early prediction of non-progression in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    T Zander
    University Hospital Cologne, Cologne, Germany Lung Clinic Merheim, Cologne, Germany Max Planck Institute, Cologne, Germany
    J Clin Oncol 27:e19054. 2009
  10. pmc Loss of heterozygosity in the Hodgkin-Reed Sternberg cell line L1236
    A Staratschek Jox
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Str 9, Cologne, 50931, Germany
    Br J Cancer 84:381-7. 2001

Collaborators

Detail Information

Publications34

  1. pmc Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
    D Re
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany
    Br J Cancer 86:1333-5. 2002
    ..Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571...
  2. ncbi request reprint Genetic instability in Hodgkin's lymphoma
    D Re
    Department of Internal Medicine I, University Hospital Cologne, Germany
    Ann Oncol 13:19-22. 2002
    ..In summary, using molecular genetics it might be possible in the near future to elucidate some of the complex genetic instabilities observed in HL...
  3. ncbi request reprint BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group
    V Diehl
    Department of Internal Medicine, University of Cologne, Germany
    J Clin Oncol 16:3810-21. 1998
    ....
  4. ncbi request reprint Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
    M R Weihrauch
    Department of Internal Medicine I, University of Cologne, Germany
    Blood 98:2930-4. 2001
    ..On the other hand, a positive PET result indicates a significantly higher risk of relapse and demands further diagnostic procedures and a closer follow-up...
  5. ncbi request reprint BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group
    V Diehl
    Department of Internal Medicine, University of Cologne, Germany
    Ann Oncol 9:S67-71. 1998
    ..The results must await confirmation (or otherwise) by the final analysis including all randomised patients and sufficiently mature data...
  6. ncbi request reprint Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells
    D Re
    Department of Internal Medicine I, University of Cologne, Germany
    Cancer Res 61:2080-4. 2001
    ..Lack of Oct-2 and Bob-1 points to a defect in transcription machinery in H-RS cells and is associated with lack of immunoglobulin gene expression in these cells...
  7. ncbi request reprint Lack of BCL10 mutations in Hodgkin's disease-derived cell lines
    D Re
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Strasse 9, 50924 Cologne, Germany
    Br J Haematol 109:420-2. 2000
    ....
  8. ncbi request reprint Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells
    M MUSCHEN
    Institute for Genetics, Department of Immunology, University of Cologne, Koln, Germany
    Cancer Res 60:5640-3. 2000
    ..In conclusion, somatic mutations of the CD95 gene occur in a fraction of cHD cases and may favor the escape of the precursor of the H/RS clone from apoptosis...
  9. ncbi request reprint Evaluation of the accuracy of FDG-/FLT-PET for early prediction of non-progression in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    T Zander
    University Hospital Cologne, Cologne, Germany Lung Clinic Merheim, Cologne, Germany Max Planck Institute, Cologne, Germany
    J Clin Oncol 27:e19054. 2009
    ..In this trial we set out to prospectively evaluate the accuracy of [18F]FDG-/[18F]FLT-PET analyses for early prediction of non-progression in chemo-naive patients with advanced NSCLC treated with erlotinib...
  10. pmc Loss of heterozygosity in the Hodgkin-Reed Sternberg cell line L1236
    A Staratschek Jox
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Str 9, Cologne, 50931, Germany
    Br J Cancer 84:381-7. 2001
    ..Further analyses of single Hodgkin-Reed Sternberg cells will reveal whether LOH affecting these regions is a recurrent event in HD and to which extent the smallest commonly affected region can be estimated...
  11. ncbi request reprint Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease-derived cell lines
    J Irsch
    Institute for Genetics, University of Cologne, Germany
    Br J Haematol 113:785-93. 2001
    ..Thus, as in other germinal centre B cell-derived lymphomas, the immunoglobulin gene locus may be frequently involved in structural chromosomal aberrations in Hodgkin's disease...
  12. ncbi request reprint Deregulation of immunoglobulin gene transcription in the Hodgkin-Reed Sternberg cell line L1236
    D Re
    Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany
    Br J Haematol 115:326-8. 2001
    ..The results showed that the mutation outside the coding region of the rearranged Ig gene in L1236 cells leads to downregulation of Ig gene expression in H-RS cells...
  13. ncbi request reprint Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group
    S Wiedenmann
    Department of Internal Medicine I, University of Cologne, Germany
    Ann Oncol 13:84-5. 2002
  14. ncbi request reprint Cell fusion is not involved in the generation of giant cells in the Hodgkin-Reed Sternberg cell line L1236
    D Re
    University of Cologne, Department of Internal Medicine I, Joseph-Stelzmannstr. 9, 50924 Cologne, Germany
    Am J Hematol 67:6-9. 2001
    ..It is thus concluded that the large multinucleated cells of the monoclonal H-RS cell line L1236 have emerged by endomitosis rather than by spontaneous cell fusion...
  15. ncbi request reprint Epidemiology and etiology of Hodgkin's lymphoma
    R K Thomas
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Ann Oncol 13:147-52. 2002
  16. ncbi request reprint Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation
    O Manzke
    University of Cologne, Department of Internal Medicine I, Joseph-Stelzmann-Str.9, D-50925 Cologne, Germany
    Int J Cancer 91:508-15. 2001
    ..However, the development of human anti-mouse antibodies points toward the requirement for new formats of bispecific proteins with reduced immunogenicity...
  17. ncbi request reprint Prognostic factors in Hodgkin's lymphoma
    T Zander
    Department of Internal Medicine I, University of Cologne, Germany
    Ann Oncol 13:67-74. 2002
    ..Furthermore, a joint effort to design new studies on large, well characterised patient groups has been initiated...
  18. ncbi request reprint Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells
    H Bohlen
    Klinik I fur Innere Medizin, Universitat zu Koln, Germany
    Cancer Res 57:1704-9. 1997
    ..Our results obtained from this autologous human B-lymphoma model have implications for the design and evaluation of new immunotherapeutic modalities for the treatment of human B-cell lymphoma with bispecific antibodies...
  19. ncbi request reprint [Factitious disorders. Hematologic, neurologic and dermatologic symptoms in a physician with factitious disorder]
    M R Weihrauch
    Klinik I fur Innere Medizin, Universitat zu Koln
    Med Klin (Munich) 96:555-60. 2001
    ..The self-reported history was inconsistent and incoherent. On physical examination neurological and dermatological disorders could be found...
  20. ncbi request reprint The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study
    L Nogova
    Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany Department of Internal Medicine I, Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany University Hospital, Koln, Germany Max Planck Institut fur neurologische Forschung mit Klaus Joachim Zulch Laboratorien der Max Planck Gesellschaft, Cologne, Germany University Hospital Cologne, Cologne, Germany Center of Familial Breast and Ovarian Cancer, Department of Gynecology and Obstetrics, University Hospital Cologne, Cologne, Germany Department of Obstetrics and Gynecology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany Institut für Pharmakologie, University Cologne, Cologne, Germany Medical Oncology and Hematology Frechen, Frechen, Germany Praxis für Hämatologie und Internistische Onkologie, Cologne, Germany Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Koeln, Germany University Hospital, Cologne, Germany West German Study Group and University of Cologne, Cologne, Berne
    J Clin Oncol 29:e13613. 2011
    ..FDG-PET might be a suitable method for the assessment of pharmacodynamic activity of E...
  21. ncbi request reprint [18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib
    M Scheffler
    Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany University Hospital Cologne, Cologne, Germany Max Planck Institute for Neurological Research, Cologne, Germany Lung Clinic, Hospital of the City of Cologne, Merheim, University Hospital Witten Herdecke, Cologne, Germany
    J Clin Oncol 29:7591. 2011
    ....
  22. pmc Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma
    B Jungnickel
    Institute for Genetics, University of Cologne, 50931 Cologne, Germany
    J Exp Med 191:395-402. 2000
    ....
  23. doi request reprint Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib
    M Bos
    Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, Germany
    Lung Cancer 81:142-3. 2013
    ..1). Our case exemplifies the need for rapid implementation of newly discovered rare genetic lung cancer subtypes in routine molecular diagnostics...
  24. ncbi request reprint An overview of the Fifth International Symposium on Hodgkin's lymphoma: recent advances in basic and clinical research
    S Wiedenmann
    Department of Internal Medicine I, University of Cologne, Germany
    Ann Oncol 13:1-3. 2002
  25. ncbi request reprint 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group
    M Sieber
    German Hodgkin s Lymphoma Study Group, Klinik fur Innere Medizin, University of Cologne, Germany
    J Clin Oncol 21:1734-9. 2003
    ....
  26. ncbi request reprint Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
    M R Weihrauch
    Department of Internal Medicine I, University of Cologne, Immunologisches Labor Haus 16, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Ann Hematol 81:20-5. 2002
    ..However, PET should not be used as the only imaging modality as it failed to detect CT-positive, active tumor regions in some cases...
  27. ncbi request reprint Efficient gene transfer in primitive CD34+/CD38lo human bone marrow cells reselected after long-term exposure to GALV-pseudotyped retroviral vector
    H Glimm
    Department of Internal Medicine I, Albert Ludwigs University, Freiburg, Germany
    Hum Gene Ther 8:2079-86. 1997
    ..The chosen strategy should be of considerable value for analyzing and improving gene therapy of the hematopoietic system...
  28. ncbi request reprint The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
    Y Minami
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 26:5023-7. 2007
    ..These results provide a rationale for treatment of patients with ERBB2-mutant or ERBB2-amplified lung tumors with HKI-272...
  29. ncbi request reprint Apoptosis-resistant phenotype of classical Hodgkin's lymphoma is not mediated by somatic mutations within genes encoding members of the death-inducing signaling complex (DISC)
    R K Thomas
    Leukemia 19:1079-82. 2005
  30. ncbi request reprint Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation
    P Hölttä
    Department of Pedodontics and Orthodontics, Institute of Dentistry, University of Helsinki, Helsinki, Finland
    Bone Marrow Transplant 29:121-7. 2002
    ..Disturbances in dental development may compromise occlusal function in poor-risk NBL patients after ASCT, especially when TBI is included in the conditioning regimen. Long-term dental follow-up and rehabilitation is required...
  31. ncbi request reprint Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone
    E Duhmke
    Canton Hospital, Basel, Switzerland
    J Clin Oncol 19:2905-14. 2001
    ..To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin's disease (HD)...
  32. pmc E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity
    A Stockinger
    Department of Biochemistry and Molecular Cell Biology, Vienna Biocenter, University of Vienna, A-1030 Vienna, Austria
    J Cell Biol 154:1185-96. 2001
    ....
  33. ncbi request reprint Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
    U Rueffer
    First Department of Internal Medicine, University Hospital Cologne, and the German Hodgkin's Study Group
    Ann Oncol 12:1307-11. 2001
    ..Further investigations have to be performed to clarify mechanisms inducing fertility defects in patients with HD...
  34. ncbi request reprint Changes in subjective quality of life among homeless adults who obtain housing: a prospective examination
    J Wolf
    The Trimbos Institute, Utrecht, The Netherlands
    Soc Psychiatry Psychiatr Epidemiol 36:391-8. 2001
    ....